Skip to main content
Effective Health Care Program

  • Jan. 1, 2005
    Topic Initiated
  • Sept. 27, 2005
    Draft Key Questions
  • Jan. 17, 2007
    Systematic Review

Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics

Systematic ReviewArchived

Archived: This report has been updated.

People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.

Excerpt

Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone are atypical antipsychotics approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia and bipolar disorder. These drugs have been studied for off-label use in the following conditions: dementia and severe geriatric agitation, depression, obsessive-compulsive disorder, posttraumatic stress disorder, and personality disorders. The atypicals have also been studied for the management of Tourette's syndrome and autism in children. The purpose of this report is to review the scientific evidence on the safety and effectiveness of such off-label uses.